Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 1, 2025Open Access

Early Use of Luspatercept After Allogeneic HSCT Improves Erythroid Recovery and Transfusion Burden

View Full Paper
Ask AI
Bookmark
Share

Authors

LWLing WangQingdao UniversitySJShiwei JinShanghai Jiao Tong UniversityMPMengmeng PanShanghai Jiao Tong University

Discussion

Loading...

Member takes

Implication

Retrospective cohort study found luspatercept improved hemoglobin levels in adults after allogeneic HSCT, suggesting better erythroid recovery and reduced transfusion burden.

Key Points

  • An 91.8% erythroid response was observed in patients treated with luspatercept after allo-HSCT, indicating improved recovery.
  • Luspatercept recipients had a greater increase in hemoglobin levels at one week, rising from 55 to 65 g/L.
  • In a retrospective cohort study, luspatercept reduced the need for RBC transfusion compared to controls, with only 10.2% requiring transfusion.
  • Findings suggest luspatercept may aid in managing anemia post-HSCT, but prospective trials are needed for confirmation.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/69054ffa1a99e50463de69aahttps://doi.org/10.21203/rs.3.rs-7900872/v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abatacept improves posttransplant survival and reduces endothelial injury syndromes in β-thalassemia major2025 · 4 citations
  2. 2Pure red cell aplasia among ABO mismatched hematopoietic stem cell transplant recipients: a 13-years retrospective study and literature review2024 · 15 citations
  3. 3Serum hepcidin level and erythropoietic activity after hematopoietic stem cell transplantation2008 · 66 citations
  4. 4Persistence of recipient plasma cells and anti‐donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non‐myeloablative haematopoietic cell transplantation2005 · 112 citations
  5. 5Lack of RBC transfusion independence by Day 30 following allogeneic hematopoietic stem cell transplant strongly predicts inferior survival and high non‐relapse mortality in acute myeloid leukemia patients2024 · 3 citations